737 related articles for article (PubMed ID: 15306098)
1. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
Algarté-Génin M; Cussenot O; Costa P
Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
3. Constitutive activation of the 41- and 43-kDa mitogen-activated protein (MAP) kinases in the progression of prostate cancer to an androgen-independent state.
Oka H; Chatani Y; Kohno M; Kawakita M; Ogawa O
Int J Urol; 2005 Oct; 12(10):899-905. PubMed ID: 16323984
[TBL] [Abstract][Full Text] [Related]
4. Tissue evidence of the testosterone role on the abnormal growth and aging effects reversion in the gerbil (Meriones unguiculatus) prostate.
Scarano WR; Vilamaior PS; Taboga SR
Anat Rec A Discov Mol Cell Evol Biol; 2006 Nov; 288(11):1190-200. PubMed ID: 17031809
[TBL] [Abstract][Full Text] [Related]
5. Herbal/hormonal dietary supplement possibly associated with prostate cancer progression.
Shariat SF; Lamb DJ; Iyengar RG; Roehrborn CG; Slawin KM
Clin Cancer Res; 2008 Jan; 14(2):607-11. PubMed ID: 18223237
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
7. Intermittent Complete Androgen Blockade in Metastatic Prostate Cancer.
Rambeaud J
Eur Urol; 1998 Dec; 35 Suppl S1():32-36. PubMed ID: 9858850
[TBL] [Abstract][Full Text] [Related]
8. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology.
Labrie F; Luu-The V; Labrie C; Simard J
Front Neuroendocrinol; 2001 Jul; 22(3):185-212. PubMed ID: 11456468
[TBL] [Abstract][Full Text] [Related]
9. Testosterone replacement therapy in prostate cancer patients: is it safe?
Umbas R; Sugiono M
Acta Med Indones; 2010 Jul; 42(3):171-5. PubMed ID: 20724773
[TBL] [Abstract][Full Text] [Related]
10. Testosterone therapy in men with prostate cancer: scientific and ethical considerations.
Morgentaler A
J Urol; 2009 Mar; 181(3):972-9. PubMed ID: 19150547
[TBL] [Abstract][Full Text] [Related]
11. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
12. Equiguard suppresses androgen-dependent LNCaP prostate cancer cell proliferation by targeting cell cycle control via down regulation of the retinoblastoma protein Rb and induction of apoptosis via the release of cytochrome c.
Lu X; Hsieh TC; Wu JM
Int J Oncol; 2004 Dec; 25(6):1801-7. PubMed ID: 15547720
[TBL] [Abstract][Full Text] [Related]
13. Androgens and prevention of prostate cancer.
Sarvis JA; Thompson IM
Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):271-7. PubMed ID: 18438176
[TBL] [Abstract][Full Text] [Related]
14. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
15. Sex steroid hormone metabolism and prostate cancer.
Soronen P; Laiti M; Törn S; Härkönen P; Patrikainen L; Li Y; Pulkka A; Kurkela R; Herrala A; Kaija H; Isomaa V; Vihko P
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):281-6. PubMed ID: 15663991
[TBL] [Abstract][Full Text] [Related]
16. The effect of androgen supplementation therapy on the prostate.
Kaufman JM
Aging Male; 2003 Sep; 6(3):166-74. PubMed ID: 14628497
[TBL] [Abstract][Full Text] [Related]
17. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
18. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
Titus MA; Schell MJ; Lih FB; Tomer KB; Mohler JL
Clin Cancer Res; 2005 Jul; 11(13):4653-7. PubMed ID: 16000557
[TBL] [Abstract][Full Text] [Related]
19. Testosterone therapy in the ageing male: what about the prostate?
Schultheiss D; Machtens S; Jonas U
Andrologia; 2004 Dec; 36(6):355-65. PubMed ID: 15541051
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer risk in testosterone-treated men.
Raynaud JP
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):261-6. PubMed ID: 17113983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]